REG - Scancell Holdings - Scancell announces CFO transition

Scancell HoldingsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260402:nRSB1255Za&default-theme=true

RNS Number : 1255Z  Scancell Holdings Plc  02 April 2026

 

2 April 2026

 

Scancell Holdings plc

Scancell announces CFO transition

David Schilansky to be appointed as financial advisor and interim CFO,
bringing extensive industry and financial experience, including leading IPOs
on Nasdaq and Euronext

Ensures continuity as Scancell advances iSCIB1+ Phase 3 trial and builds
shareholder value

 

Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to
treat cancer, announces David Schilansky, a highly experienced senior
healthcare executive and entrepreneur, and Entrepreneur-in-Residence with
Redmile Group, has been appointed (with immediate effect) to serve as a
financial advisor and shall become interim Chief Financial Officer (CFO) later
in April. Current CFO Sath Nirmalananthan has indicated he will be leaving the
Company and will step down from the Board of Directors as of April 24, 2026 to
pursue other professional opportunities.  Scancell has launched a global
recruitment process for a permanent CFO.

Dr Phil L'Huillier, CEO of Scancell, said: "David brings broad and strategic
financing expertise to Scancell and will be a strong interim CFO, ensuring
continuity and progress in our strategy. We remain laser focused on delivering
iSCIB1+ to patients and building shareholder value. Having David in place
enables us to seamlessly advance our constructive financing and partnering
discussions on our lead ImmunoBody® iSCIB1+, now with the recently obtained
strong regulatory feedback in hand. Further, David brings valuable investor
engagement and strategic financing expertise, including Nasdaq listing
experience that will help guide the company as we explore a potential listing
in the US."

Phil L'Huillier added: "Sath has played an important role at Scancell,
providing strong financial guidance and preparing us for our next phase of
development. On behalf of the Scancell team, I would like to thank Sath for
his dedicated and committed efforts to Scancell. We wish him all the best in
his future endeavours."

David Schilansky is a seasoned pharma and biotech executive and is currently
concluding his role as Chief Executive Officer of Ariceum Therapeutics and
commencing as Venture Partner and Entrepreneur-in-Residence at Redmile Group.
He was previously CEO and co-founder of Home Biosciences from 2020 to 2025,
which created three biotech companies (One Biosciences, Sequantrix and Apikal
Therapeutics). From 2011 to 2019, he co-headed DBV Technologies, leading its
IPOs on Nasdaq and Euronext, raising a total of more than $1 billion. Prior to
that, he held several leadership roles in finance, including Group CFO at
Ipsen.

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014 (MAR).

-ENDS-

Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage biotechnology
company developing targeted off-the-shelf active immunotherapies, to generate
safe and long-lasting tumour-specific immunity for a cancer-free future.
iSCIB1+, the lead product from their DNA ImmunoBody® platform has
demonstrated safe, durable and clinically meaningful benefit as a monotherapy
as well as additional benefit when combined with checkpoint therapies in a
Phase 2 trial in melanoma. Modi-1, the lead peptide immunotherapy from their
Moditope® platform, is being investigated in a Phase 2 study in a broad range
of solid tumours. In addition, Scancell's wholly owned subsidiary, GlyMab
Therapeutics Ltd., has been established with the intention to hold and develop
an exciting early-stage pipeline of high affinity GlyMab® antibodies
targeting tumour specific glycans, two of which already have been licensed and
are being developed by Genmab A/S, an international biotechnology company and
global leader in the antibody therapeutics space.

 

For more information please contact:

 Scancell Holdings plc                                   +44 (0) 20 3709 5700
 Phil L'Huillier, CEO

 Jean-Michel Cossery, Chairman

 Panmure Liberum (Nominated Adviser and Joint Broker)    +44 (0) 20 7886 2500
 Emma Earl, Will Goode, Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)                          +44 (0) 20 3705 9330

 David Wilson, Claes Spang

 Investor and media relations                            +44 (0) 20 7483 284853

 Mary-Ann Chang                                          MaryAnnChang@scancell.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAIBMITMTTMBLF



            Copyright 2019 Regulatory News Service, all rights reserved